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Abstract 
In recent years, several studies have reported a correlation between adenomyosis and 
major obstetric adverse effects. Implantation failures can be caused by changes in the 
expression of some molecules, referred to as "implantation markers", which are expressed by 
the endometrium and are required for successful interaction between the embryo and 
endometrium. The purpose of the study was to determine the features of the proteomic 
profile of the endometrium in women with adenomyosis, depending on their fertility.  
Material and methods. A comparative immunohistochemical (IGC) analysis of 102 eutopic 
endometrial specimens from women of reproductive age with adenomyosis and infertility 
(group I) was performed; from 20 nonpregnant women with adenomyosis who had a history of 
desired pregnancy and ended in childbirth and did not record episodes of miscarriages (group 
II), as well as from 30 conditionally gynecologically healthy women who applied for the 
introduction of an intrauterine system for contraception (control group C). A biopsy of the 
eutopic endometrium was performed on P+6 day of the menstrual cycle, during the period of 
the expected implantation window, with the help of aspiration pipel-curette. In 
immunohistochemical (IGC) determination of the proteomic profile of the endometrium 
HOXA10 was stained with monoclonal antibodies (MAB) to HOXA10 (sc-17159, Santa Cruz 
Biotechnology, USA); LIF - murine MAB against LIF (J-14F: SC-80159, Santa Cruz 
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Biotechnology Inc., USA); sgp130 - goat polyclonal antibodies (PAB) anti-gp130 (BAF 228, 
supplied 50 μg / ml, R&D Systems); IL-6 - primary rabbit antibodies (code No CXH1-066LS, 
supplied as rabbit IgG 20 µg / ml; Cambridge Bioscience, UK). Results. It was found that 
important factors of reproductive disorders in women with adenomyosis are: changes in the 
proteomic profile of the eutopic endometrium on the day of the expected implant window, 
such as a decrease in HOXA 10 expression in the stroma by 1.52 (p<0.01) and in the glands 
by 1.46 times (p<0.01), LIF in glands - in 1.12 (p<0.01) and sgp130 - in 2.52 (p<0.01), as 
well as increased secretion in glands of IL-6 in 1,99 (p<0.01) times. In fertile women with 
adenomyosis, less pronounced changes in the proteomic profile of the eutopic endometrium 
are observed, which creates the conditions for successful realization of reproductive 
intentions, including a decrease in expression of HOXA 10 in the stroma by 1.48 times 
(p<0.01), in the glands - in 1.12 (p>0.05); secretion in glands of LIF - in 1.06 (p>0.05) and 
gp130 - in 1.98 (p<0.01); increased IL-6 1.08 times (p<0.05). Conclusions. Changes in the 
proteomic profile of the endometrium play an important role in the occurrence of reproductive 
disorders in adenomyosis.  
Key words: adenomyosis; endometrium; infertility; proteomic profile; HOXA10; 
Leukemia inhibitory factor; glycoprotein 130; interleukin-6. 
 
Adenomyosis, one of the main varieties of genital endometriosis, occupies a 
significant place in the structure of gynecological morbidity and presents an urgent problem 
of modern gynecology and obstetrics [6, 10, 15]. Genital endometriosis affects every tenth 
woman in reproductive age, and the prevalence of adenomyosis in patients with endometriosis 
ranges from 20 to 70 % [3, 9]. However, despite this, previously existing studies, due to the 
difficulty of clinical and instrumental diagnosis of adenomyosis, paid little attention to its 
impact on the course and outcomes of pregnancy, as well as the development of methods for 
pre-conceptual preparation and management of pregnant women with adenomyosis.  
In recent years, several studies have reported a correlation between adenomyosis and 
major obstetric adverse effects such as miscarriage, premature rupture of the membranes, and 
premature birth, gestational hypertension, pre-eclampsia, preeclampsia, preeclampsia, 
gestational diabetes, obstetric bleeding, placental presentation [1, 2, 4, 7, 8].  
An important issue is to elucidate the pathogenetic mechanisms that lead to 
reproductive disorders in adenomyosis. Implantation failures can be caused by changes in the 
expression of some molecules, referred to as "implantation markers", which are expressed by 
the endometrium and are required for successful interaction between the embryo and 
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endometrium [13]. During the implantation window, the expression of some of these markers 
changes in the eutopic endometrium of women with adenomyosis, suggesting that changes in 
the proteomic profile of the endometrium may disrupt pregnancy progression. 
Therefore, the purpose of the study was to determine the features of the proteomic 
profile of the endometrium in women with adenomyosis, depending on their fertility. 
Material and methods 
A comparative immunohistochemical (IGC) analysis of 102 eutopic endometrial tube 
specimens from women of reproductive age with adenomyosis and infertility (group I) was 
performed; from 20 nonpregnant women with adenomyosis who had a history of desired 
pregnancy and ended in childbirth and did not record episodes of miscarriage (group II), as 
well as from 30 conditionally gynecologically healthy women who applied for the introduction 
of an intrauterine system for contraception (control group C). 
A biopsy of the eutopic endometrium was performed on P+6 day of the menstrual 
cycle, during the period of the expected implantation window, with the help of aspiration 
pipel-curette. When evaluating the features of the proteomic profile of the eutopic 
endometrium, expression on the day of the expected window of implantation of the homeobox 
gene-10 (HOXA10), leukemia inhibitory factor (LIF), soluble glycoprotein 130 (gp130), 
interleukin-6 (IL-6) (6) was studied. The obtained endometrial samples were placed in neutral 
buffered 10 % formalin solution (pH 7.4) and fixed for 24 hours. After dehydration, the pieces 
were poured into paraffin. On a rotary microtome Microm HM325 with STS slice transfer 
system (Carl Zeiss, Germany), serial histologic sections of 4 μm thickness were made, which 
were then stained with hematoxylin and eosin. 
For further immunohistochemical (IHC) studies, part of the serial paraffin sections 
were placed on an adhesive coated Super Frost Plus glass (Menzel, Germany).  
IHC immunostaining of HOXA10 in the endometrium was performed using 
monoclonal antibodies (MAB) to HOXA10 (sc-17159, Santa Cruz Biotechnology, USA). In 
determining HOXA10 normal goat IgG (Santa Cruz Biotechnology, USA) was used as a 
negative control. Biotinylated secondary α-goat antibodies from Vector Laboratories (UK) 
were applied for 1 hour at 4°C. The slides were washed with PBS, incubated in avidin-biotin-
peroxidase complex (Vector Laboratories, UK) for 15 min. at room temperature, washed in 
PBS and incubated for 5 min. in diaminobenzidine. A 20-second exposure to hematoxylin 
was used as the opposite. The drugs were rehydrated through ethanol for 3 min and washed 
with xylene.  
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The level of IHC immunostaining of LIF in the endometrium was determined using 
murine MAB against LIF (J-14F:SC-80159, Santa Cruz Biotechnology Inc., USA). 
ImmunoCruz™: sc-2050 or ABC: sc-2017 murine IgG staining systems were used as 
secondary reagents according to the manufacturer's instructions. 
For IHC endometrial immunostaining of interleukin IL-6 primary rabbit antibodies 
(code No CXH1-066LS supplied as rabbit IgG 20 µg / ml; Cambridge Bioscience, UK) were 
used, which were diluted 1: 250 in 1 % BSA-PBS (bovine serum albumin + sodium phosphate 
buffer) and added to sections. The sections were then incubated for 60 min. at 37 °C in a 
humidified chamber. Rabbit IgG (20 mg / ml, DAKO Corp., Denmark) diluted to the same 
concentration was used as a negative control. The sections were treated identical to the 
immunoprotection of IL-6R described below.  
Immunostaining of gp130 was performed with primary goat polyclonal antibodies 
(PAB) anti-gp130 (BAF 228, supplied 50 μg / ml, R&D Systems), which was added for 1 
hour at a dilution of 1:20 in 5 % rabbit serum / 1 % - of BSA-PBS. The control antibody 
(I5256, goat IgG, Sigma) was added with the same concentration of protein to control slice 
color. 
 In the quantification of HOXA10 used the formula H-score = Σ Pi (i + 1), where the 
intensity of HOXA10 nuclear staining was 0, 1, 2 or 3 (none, weak, moderate, strong), and Pi 
- the percentage of colored nuclei for each intensity. When evaluating endometrial expression 
of LIF, sgp130, and IL-6 counted positively stained cells in three fields of view and calculated 
the percentage of positive cells relative to at least 1000 cellular elements of the stroma or 
glands.  
The examination of histological specimens in light was performed on an Olympus 
AX70 microscope (Japan) with an Olympus DP50 digital video camera connected to a 
personal computer. Microphotography and morphometry were performed using ANALYSIS 
Pro 3.2 (SoftImaqinq, Germany). 
Statistical analysis of the results of the study was carried out with the calculation of 
arithmetic mean (M), standard deviation error (± SE), to use the Student's t-test to compare 
parametric values. 
Results and Discussion 
The mean age of women in group I was 28.23 ± 0.28 years, group II was 29.15 ± 0.64, 
group CI was 27.50 ± 0.46 and was not statistically significant between the groups. The 
distribution of patients in the groups by mass-growth characteristics was also homogeneous: 
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body mass index in infertile women with adenomyosis was 22.29 ± 0.34 kg / m2, in fertile 
persons with adenomyosis - 23.10 ± 0.85 kg / m2, in the control group - 23,20 ± 0,38 kg / m2.  
The duration of infertility in group I was 5.15 ± 0.363 years.  
An important factor that may be involved in impaired implantation in women with 
adenomyosis is the altered function of the HOXA-10 gene. This gene is part of the 
transcription factors containing homeobox required for embryonic development and proper 
growth of the endometrium in adulthood [17], and in women with adenomyosis its expression 
is much lower in the middle secretory phase compared to fertile control [5]. In the study, the 
immunostaining of HOXA10 in the eutopic endometrium was observed in both stroma and 
endometrial glands, it was predominant in stromal cells. In pregnant women of reproductive 
age with adenomyosis and reproductive disorders, the expression of HOXA10 in the stroma 
was 434.64 ± 9.42 % and in the glands –171.51 ± 4.36 %; in pregnant women with 
adenomyosis, in whom the desired pregnancy ended in childbirth and had no miscarriages, - 
446,13 ± 21,88 and 222,94 ± 11,67 %, as well as in conditionally gynecologically healthy 
pregnant women without adenomyosis, who have a history of the desired pregnancy ended 
with childbirth - 660.27 ± 11.54 and 250.61 ± 6.92 % (Fig. 1).  
 
   
Fig. 1 HOXA10 expression in eutopic endometrium at P + 6 day: 1 - in infertile 
patients with adenomyosis; 2 - in fertile persons with adenomyosis; 3 - in women of the 
control group. IGC from MAB to HOXA10, magnification × 150. 
 
1 3 2 
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HOXA10 expression in eutopic endometrial stroma in infertile women with 1.52 
(p<0.01) adenomyosis and 1.88-fold in fertile women with adenomyosis was less than that in 
control women, whereas in the glands it was statistically significantly less by 1.46 times 
(p<0.01) only in group I, and in group II it was less by 1.12 times, but it is unbelievable. 
The results obtained are in agreement with those of C.P. Fischer et al. (2011) that in 
women with adenomyosis, HOXA10 expression is significantly lower in the middle secretory 
phase compared to the fertile control [5]. 
LIF is associated with endometrial susceptibility and lower in women with infertility 
compared to healthy controls. A. Winship et al. (2015) in mouse experiments found that LIF 
plays an important role in trophoblast invasion in vivo and can facilitate cross-linking 
between trophoblast and deciduous immune cells to provide adequate remodeling of the spiral 
arteries [16]. Immunostaining of LIF was observed in the cytoplasm of endometrial glands 
with predominant localization in the apical part, in the superficial epithelium, slightly in the 
stroma. Only epithelial LIF expression in the endometrium was evaluated in the study. Hscore 
LIF in eutopic endometrium of persons with infertility and adenomyosis was 250.60 ± 3.69 
%, in fertile women with adenomyosis - 264.49 ± 8.97 %, in control - 280.81 ± 3.53 % (Fig. 
2). 
   
Fig. 2 Expression of LIF in eutopic endometrium at P + 6 day: 1 - in infertile patients 
with adenomyosis; 2 - in fertile persons with adenomyosis; 3 - in women of the control group. 
IHC from MAB to LIF, magnification × 300. 
1 3 2 
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Expression of LIF in eutopic endometrium in infertile women with adenomyosis 
relative to the control group was reduced by 1.12 (p<0.01) times, respectively, whereas in the 
group of fertile patients was not significantly different (p> 0.05). C.F. Yen et al. (2017) also 
showed a significant decrease in LIF receptor expression and a decrease in subsequent 
signaling activation, strongly suggesting a working model of how implantation markers, 
including LIF, can affect the endometrium of patients with adenomyosis. These molecular 
changes support the reduced rate of implantation reported in patients with adenomyosis [18]. 
Expression in the eutopic endometrium of gp130, the LIF receptor and IL-6, was 
mainly expressed in the cytoplasm of gland epithelial cells and was also found in vascular 
endothelium. Its Hscore was equal in group I 311.52 ± 4.67 %, in group II - 397.42 ± 13.48 % 
and in group C - 786.27 ± 9.88 % (Fig. 3). 
 
   
 
Fig. 3 Expression of gp130 in eutopic endometrium on P+6 day: 1 - in infertile 
patients with adenomyosis; 2 - in fertile persons with adenomyosis; 3 - in women of the 
control group. IHC with PAB against gp130, magnification × 300 (1, 2), × 400 (3). 
 
Expression of gp130 in the eutopic endometrium of infertile patients with 
adenomyosis was reduced relative to the same indicator of the control group by 2.52 times 
(p<0.01) and in fertile patients with adenomyosis - by 1.98 (p<0.01). A characteristic feature 
was a more pronounced decrease in the expression of gp130 in women with adenomyosis and 
infertility at 1.28 (p<0.01) than in fertile individuals with adenomyosis. 
1 3 2 
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According to H. Pitman et al. (2013), altered expression of IL-6 and its receptors is 
observed in various cell types in the placental bed (stromal myometrium, glandular 
epithelium, interstitial extravillus trophoblastic cells, vascular smooth muscle cells and 
endothelial cells) in spontaneous 14 innocence. The expression of IL-6 in the study was the 
most intense in the cells of the glandular and superficial epithelium, so the work evaluated the 
epithelial staining of IL-6.  
The most pronounced IHC staining of cytoplasm of the glandular epithelium of MAB 
against IL-6 was observed in infertile women with adenomyosis (447.15 ± 3.47 %), which 
was higher than in fertile persons with adenomyosis (241.68 ± 7.37 %) in 1.85 times (p<0.01) 
and women in the control group (224.66 ± 3.47 %) - 1.99 (p<0.01). IL-6 expression in the 
eutopic endometrium was not statistically different between groups II and C (Fig. 4).  
 
   
 
Fig. 4 Expression of IL-6 in eutopic endometrium on P + 6 day: 1 - in infertile patients 
with adenomyosis; 2 - in fertile persons with adenomyosis; 3 - in women of the control group. 
IHC with MAB against IL-6, magnification ×400 (1, 2), ×300 (3). 
 
Conclusions 
One factor in reproductive disorders in women with adenomyosis and infertility is the 
change in the proteomic profile of the eutopic endometrium on the day of the expected implant 
window, which includes a decrease in HOXA 10 expression compared to stroma control of 
1.52 (p<0.01) and glands in 1,46-fold (p<0.01); a decrease in LIF expression glands of 1.12 
1 3 2 
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(p<0.01) and gp130 - 2.52-fold (p<0.01), and an increase in IL-6 gland secretion of 1.99 (p<0, 
01) times. 
In fertile women with adenomyosis, less pronounced changes in the proteomic profile 
of the eutopic endometrium are observed, which creates the conditions for successful 
realization of reproductive intentions, including a decrease in expression of HOXA 10 in the 
stroma by 1.48 times (p<0.01), in the glands - in 1.12 (p>0.05); secretion in glands of LIF - in 
1.06 (p>0.05) and gp130 - in 1.98 (p<0.01); increased IL-6 1.08 times (p<0.05). 
Changes in the proteomic profile of the endometrium play an important role in the 
occurrence of reproductive disorders in adenomyosis. 
 
References 
1. Berlac JF, Hartwell D, Skovlund CW, Langhoff-Roos J, Lidegaard O. 
Endometriosis increases the risk of obstetrical and neonatal complications. Acta Obstet 
Gynecol Scand. 2017;96(6):751-760. doi: 10.1111/aogs.13111.  
2. Conti N, Cevenini G, Vannuccini S, Orlandini C, Valensise H, Gervasi MT, et 
al. Women with endometriosis at first pregnancy have an increased risk of adverse obstetric 
outcome. J Matern Fetal Neonatal Med. 2015;28(15):1795-8. doi: 
10.3109/14767058.2014.968843.  
3. Di Donato N, Montanari G, Benfenati A, Leonardi D, Bertoldo V, Monti G, et 
al. Prevalence of adenomyosis in women undergoing surgery for endometriosis. Eur J Obstet 
Gynecol Reprod Biol. 2014; 181: 289-293. doi: 10.1016/j.ejogrb.2014.08.016. 
4. Exacoustos C, Lauriola I, Lazzeri L, De Felice G, Zupi E. Complications 
during pregnancy and delivery in women with untreated rectovaginal deep infiltrating 
endometriosis. Fertil Steril. 2016; 106: 1129-1135. e1. doi: 10.1016/j.fertnstert.2016.06.024.  
5. Fischer CP, Kayisili U, Taylor HS. HOXA10 expression is decreased in 
endometrium of women with adenomyosis. Fertil Steril. 2011 Mar 1;95(3):1133-6. doi: 
10.1016/j.fertnstert.2010.09.060.   
6. Gladchuk IZ, Rozhkovskaya NN, Garbuzenko ND, Stamova NA. Age 
characteristics of uterine motility in infertile women with adenomyosis, uterine fibroids and 
their combination. The health of woman. 2016;3(109):149–152.  
7. Glavind MT, Forman A, Arendt LH, Nielsen K, Henriksen TB. Endometriosis 
and pregnancy complications: a Danish cohort study. Fertil Steril. 2017;107(1):160-166. doi: 
10.1016/j.fertnstert.2016.09.020.  
 661 
8. Harada T, Taniguchi F, Onishi K, Kurozawa Y, Hayashi K, Harada T, et al. 
Obstetrical complications in women with endometriosis: a cohort study in Japan. PLoS One. 
2016; 11(12):e0168476. doi: 10.1371/journal.pone.0168476.  
9. Hashimoto A, Iriyama T, Sayama S, Nakayama T, Komatsu A, Miyauchi A, et 
al. Adenomyosis and adverse perinatal outcomes: increased risk of second trimester 
miscarriage, preeclampsia, and placental malposition. J Matern Fetal Neonatal Med. 
2018;31(3):364-369. doi: 10.1080/14767058.2017.1285895.  
10. Kaminsky BB, Prokopovich EV. An alternative to hormonal and non-steroidal 
anti-inflammatory drugs in the treatment of secondary dysmenorrhea caused by adenomyosis. 
The health of woman. 2018; 4: 66-70.  
11. Kutsenko II, Kravtsova EI, Simovonik AN, Rudeeva OA. Ultrasound diagnosis 
of adenomyosis I degree of spread. Modern problems of science and education. 2017: 6. 
URL: http://www.science-education.ru/en/article/ view? Id = 27350.  
12. Mannini L, Sorbi F, Noci I, Ghizzoni V, Perelli F, Di Tommaso M, et al. New 
adverse obstetrics outcomes associated with endometriosis: a retrospective cohort study. Arch 
Gynecol Obstet. 2017; 295: 141-151.  
13. Mikolajczyk M, Wirstlein P, Skrzypczak J. Leukaemia inhibitory factor and 
interleukin-11 levels in uterine flushings of infertile patients with endometriosis. Hum 
Reprod. 2006 Dec;21(12):3054-8.  
14. Pitman H, Innes BA, Robson SC, Bulmer JN, Lash GE. Altered expression of 
interleukin-6, interleukin-8 and their receptors in decidua of women with sporadic 
miscarriage. Hum Reprod. 2013;28(8):2075-86. doi: 10.1093/humrep/det233.  
15. Vdovichenko JuP, Gnip IP, Vorobiy VD. Optimization of diagnostics and 
endoscopic treatment of adenomyosis and disorders of reproductive function. Woman's 
health. 2015; 6:149–151.  
16. Winship A, Correia J, Zhang JG Nicola NA, Dimitriadis E. Leukemia 
Inhibitory Factor (LIF) Inhibition during Mid-Gestation Impairs Trophoblast Invasion and 
Spiral Artery Remodeling during Pregnancy in Mice. PLoS One. 2015;10(10):e0129110. doi: 
10.1371/journal.pone.0129110.  
17. Xu B, Geerts D, Bu Z, Ai J, Jin L, Li Y, et al. Regulation of endometrial 
receptivity by the highly expressed HOXA9, HOXA11 and HOXA10 HOX-class homeobox 
genes. Hum Reprod. 2014;29(4):781-90. doi: 10.1093/humrep/deu004.  
18. Yen CF, Liao SK, Huang SJ, Tabak S, Arcuri F, Lee CL, et al. Decreased 
Endometrial Expression of Leukemia Inhibitory Factor Receptor Disrupts the STAT3 
 662 
Signaling in Adenomyosis During the Implantation Window. Reprod Sci. 2017;24(8):1176-
1186. doi: 10.1177/1933719116681515.  
